Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($1.22), $0.01 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $8.71 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.